Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong strategic moves and financial health. Pfizer's R&D productivity, cost savings initiatives, and raised EPS guidance are positive indicators. The Q&A revealed confidence in key trials and strategic legal actions. Despite some unclear responses, the overall sentiment is positive, with optimistic guidance and strategic expansions in multiple markets. The lack of market cap data limits precise impact prediction, but the positive factors outweigh negatives, suggesting a positive stock price movement.
Key Financial Performance
Revenue $16.7 billion for Q3 2025, a decrease of 7% operationally year-over-year. The decline was largely driven by reduced demand for COVID products like Paxlovid and Comirnaty due to lower disease incidence and last year's one-time government stockpiling.
Non-COVID Products Revenue Grew 4% operationally year-over-year in Q3 2025, driven by strong contributions from products like Eliquis, the Vyndaqel family, and Nurtec.
Adjusted Gross Margin Approximately 76% for Q3 2025, reflecting product mix and strong cost management within the manufacturing footprint.
Adjusted Operating Expenses $7 billion for Q3 2025, an increase of 21% operationally year-over-year, primarily due to acquired in-process R&D expenses from the 3SBio transaction. Excluding this, operating expenses contracted by approximately $150 million.
Adjusted Diluted EPS $0.87 for Q3 2025, ahead of expectations due to strong gross margin and cost management performance. This includes a $0.20 headwind from acquired in-process R&D expenses.
Vyndaqel Family Revenue Achieved 7% year-over-year global operational growth in Q3 2025, driven by strong demand and market leadership in treating ATTR cardiomyopathy.
Nurtec Revenue Achieved 22% year-over-year operational growth in Q3 2025, driven by strong uptake in key markets and effective consumer campaigns.
Padcev Revenue Achieved 13% year-over-year global operational growth in Q3 2025, driven by expanded utilization and its establishment as a standard of care for certain cancer treatments.
Prevnar Family Revenue (International) Achieved 17% year-over-year growth in Q3 2025, driven by launches in key markets and strong performance in pediatric pneumococcal vaccination.
Abrysvo Revenue Achieved 75% year-over-year operational growth in Q3 2025, driven by expanded access in key markets.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Metsera Acquisition: Pfizer is pursuing the acquisition of Metsera to strengthen its position in the obesity therapeutic area. The company believes this acquisition will create substantial value for shareholders and advance innovation.
3SBio Licensing Agreement: Pfizer has made progress with its licensing agreement with 3SBio, focusing on the PD-1 VEGF bispecific SSGJ-707 for metastatic colorectal cancer. Encouraging Phase II data was presented at the European Society for Medical Oncology meeting.
R&D Pipeline: Pfizer's R&D pipeline is growing, with advancements in cancer immunotherapy and other key programs. The company presented over 45 abstracts and 5 late-breaking presentations at the ESMO meeting.
Cardiometabolic Presence: Pfizer plans to reinvigorate its cardiometabolic presence by leveraging its commercial and scientific strengths, particularly with the Metsera acquisition.
Vaccines Portfolio: Pfizer's Prevnar family achieved 17% year-over-year international growth, and the company remains a leader in pediatric pneumococcal vaccination with public funding in 140 national immunization programs.
Lung Cancer Market: Pfizer is targeting the lung cancer market, expected to reach $70 billion by 2030, with its growing portfolio of small molecules, ADCs, and bispecifics.
Cost Management: Pfizer achieved $1.5 billion in savings from its manufacturing optimization program and expects $7.7 billion in savings by 2027.
Operational Efficiency: The company has streamlined decision-making and improved operating margins, with adjusted gross margins remaining in the mid-to-upper 70s.
Revenue Performance: Non-COVID products grew 4% operationally, with strong contributions from Eliquis, Vyndaqel, and Nurtec.
U.S. Government Agreement: Pfizer reached an agreement with the U.S. government to lower prescription drug costs and align prices with other developed countries, providing a 3-year grace period from certain tariffs.
Focus on Innovation: Pfizer is focusing on innovation and long-term shareholder value, with investments in R&D and strategic acquisitions like Metsera and 3SBio.
Pipeline Expansion: The company is expanding its pipeline with promising late-stage assets, including advancements in cancer therapies and vaccines.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Policy Risks: The agreement with the U.S. government to lower prescription drug costs and align prices with other developed countries introduces potential financial pressure. Additionally, the 3-year grace period from U.S. tariffs requires further investment in U.S. manufacturing, which could strain resources.
Acquisition and Antitrust Challenges: The proposed acquisition of Metsera faces significant antitrust risks, particularly with Novo Nordisk's competing offer, which Pfizer claims violates antitrust laws. Legal actions and regulatory hurdles could delay or derail the acquisition, impacting strategic plans in the obesity therapeutic area.
COVID-19 Product Decline: Revenues from COVID-19 products, including Paxlovid and Comirnaty, have significantly declined due to reduced demand and lower infection rates. This decline poses a challenge to offsetting revenue losses from other areas.
Pipeline and R&D Risks: While the R&D pipeline shows promise, there are risks associated with advancing late-stage programs, including regulatory approvals and clinical trial outcomes. Delays or failures in these areas could impact future growth.
Financial and Operational Efficiency: Cost improvement measures and manufacturing optimization programs are critical to maintaining margins. However, achieving $7.7 billion in savings by 2027 requires disciplined execution, and any setbacks could affect profitability.
Market Competition: Intense competition in key therapeutic areas, such as cardiometabolic and oncology, could impact Pfizer's market share and revenue growth. Competitors' advancements may challenge Pfizer's leadership in these markets.
Economic and Market Conditions: Lower vaccination rates and COVID infection rates, along with potential economic uncertainties, could further impact revenue projections and operational stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Pfizer expects full year 2025 revenues to be in the range of $61 billion to $64 billion. Non-COVID products are performing well operationally, but there is softness in COVID products due to lower vaccination and infection rates.
Adjusted Diluted EPS Guidance: Pfizer has raised and narrowed its full year 2025 adjusted diluted earnings per share guidance to $3.00 to $3.15, reflecting strong performance and a more efficient cost structure.
R&D and Cost Management: Adjusted R&D expenses are expected to be in the range of $10 billion to $11 billion for 2025. Pfizer is implementing cost improvement programs, targeting $7.7 billion in savings by the end of 2027, with $1.5 billion in savings from manufacturing optimization by the end of 2027.
Capital Allocation: Pfizer plans to continue investing in its business, including R&D and business development, while maintaining and growing its dividend. The company expects to bring its leverage back to target levels over time after the Metsera transaction.
Pipeline and Product Development: Pfizer is advancing its late-stage R&D pipeline, including potential Phase III starts for its 25-valent vaccine candidate in 2026 and other key programs. The company is also focusing on expanding its lung cancer portfolio, targeting a market expected to reach $70 billion by 2030.
COVID-19 Products: Pfizer notes lower-than-anticipated COVID trends but has derisked its adjusted diluted EPS guidance to account for this.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Commitment: Pfizer remains committed to its dividend, as highlighted in the earnings call. The company has returned $7.3 billion to shareholders via quarterly dividends in the first nine months of 2025.
Share Repurchase: Pfizer's capital allocation strategy includes making value-enhancing share repurchases. However, no specific share buyback program details were disclosed in the transcript.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the market share dynamics and pricing challenges for Vyndamax?
A:Vyndamax faces new competition but remains the only ATTR-CM product with statistically significant reductions in mortality and CV-related hospitalizations. It has 90% access across the U.S. Despite strong demand growth and market share leadership, net sales were impacted by IRA manufacturer rebates and payer contracting. Volume growth is expected to continue, but gross-to-net headwinds will persist.
Q:How is Padcev performing commercially, and what are the expectations for its growth?
A:Padcev has about 55% share among cisplatin-ineligible patients and 45%-50% among cisplatin-eligible patients. A shift from a drop ship to a wholesaler model caused a one-time growth in Q2 sales, impacting Q3 comparisons. Growth is expected to resume in Q4, with potential expansion from ongoing trials (303 and 304) targeting a patient population of 22,000.
Q:What is Pfizer's stance on Novo's acquisition of Metsera?
A:Pfizer views Novo's acquisition of Metsera as an illegal attempt to bypass antitrust laws and eliminate competition. Pfizer is pursuing all legal resources to challenge the acquisition.
Q:What is Pfizer's plan if the Metsera acquisition does not work out?
A:Pfizer will continue to pursue business development opportunities across its four therapeutic areas. Investments in innovative medicines will continue, and guidance for 2026 will incorporate these factors.
Q:What are Pfizer's priorities regarding manufacturing investments and operational cost efficiencies?
A:Pfizer is investing in U.S. production capacity while improving its manufacturing operating infrastructure. Both priorities are being pursued simultaneously and will be detailed further in 2026 guidance.
Q:What factors supported Pfizer in obtaining early FTC clearance for a deal?
A:The FTC made its decision independently, likely recognizing the antitrust concerns of a foreign company attempting to dominate the market. Pfizer believes the clearance demonstrates the strength of its deal.
Q:Why was the MagnetisMM-5 trial data pushed to 2026, and how does it compare to J&J's trial?
A:The MagnetisMM-5 trial is event-driven, and delays are due to fewer events occurring, which is often a positive sign. Pfizer is monitoring the trial closely and expects data early next year.
Q:What are the Paxlovid dynamics for the quarter?
A:There were no significant changes in Paxlovid pricing. Variations may be due to channel mix, but trends are expected to continue into Q4.
Q:What is Pfizer's confidence in the upcoming Phase III EZH2 readout in CRPC?
A:Pfizer is confident due to previous randomized data showing significant PFS benefits in all comers in late-line metastatic castration-resistant prostate cancer. The dose selected for Phase III has been optimized for reduced GI adverse events.
Q:Is Pfizer's $9 billion COVID-19 sales target for the year still achievable?
A:The low end of Pfizer's revenue guidance assumes modest COVID-19 uptake for the rest of the year. Peaks in COVID-19 cases could increase utilization, but earnings guidance has been adjusted to account for potential shortfalls.
Q:What is Pfizer's perspective on GLP-1 pricing and its impact on the obesity landscape?
A:Pfizer has accounted for potential price declines in GLP-1s in its calculations. The company remains confident in its strategy despite competitive pricing pressures.
Q:Why was the initiation of the pivotal trial for the adult 25-valent pneumococcal program delayed?
A:The delay aligns the adult and pediatric studies, with fourth dose data from the pediatric study expected early next year. The vaccine candidate is designed to address serotype 3, which constitutes up to 20% of infections in the U.S. and EU.
Q:What are Pfizer's thoughts on MFN agreements and their impact on international revenues?
A:Pfizer believes the price differential between the U.S. and international markets is unsustainable. The company is working with the U.S. government to address pricing issues and may forgo reimbursement in certain countries if fair pricing cannot be achieved.
Q:What is Pfizer's determination to pursue Metsera despite challenges?
A:Pfizer conducted extensive due diligence and believes Metsera offers significant value. The company views Novo's actions as an attempt to eliminate competition and is committed to pursuing legal action.
Q:What are Pfizer's plans for dividends, deleveraging, and share repurchases?
A:Pfizer prioritizes productivity improvements, R&D investments, and offsetting LOEs. Share repurchases are not a near-term priority as the company focuses on deleveraging and business development.
Q:What is Pfizer's balance sheet capacity for dealmaking, and when can we expect data from the 3SBio deal?
A:Pfizer has approximately $13 billion in capacity for business development. Data from the 3SBio deal is expected in 2026, with updates on the development plan to be provided in the coming weeks.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about the timing of the legal process for Metsera, specific financial impacts of MFN agreements for 2026, and detailed factors influencing FTC clearance. Additionally, responses to questions about GLP-1 pricing and the obesity landscape, as well as the delay in the 25-valent pneumococcal program, lacked detailed explanations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BRAF
LY
Metsera transaction
Phase II
Phase III
Presidential Symposium
RD expense
RD transaction
SA
Saharan Africa
Sub Saharan
acquisition Metsera
adult market
agreement government
cisplatin muscle
clarity investment
deal
hormone prostate
licensing
market leader
medicine patient
merger agreement
mutation
patient cisplatin
process RD
product demand
program development
prostate cancer
risk recurrence
strength RD
transaction leverage
uptake
valent
PFE Transcript
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Pfizer Inc. (PFE) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary indicates declining revenue and EPS, primarily due to reduced COVID-19 product sales and increased R&D expenses. The absence of strategic updates or positive market insights, coupled with potential regulatory and economic risks, suggests a negative outlook. The lack of clear guidance or shareholder return plans further supports a negative sentiment. Given these factors, the stock price is likely to experience a negative movement in the range of -2% to -8% over the next two weeks.
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
PFE Slides
PFE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
